IMPORTANCE: Cerebrovascular disease and Alzheimer disease (AD) frequently co-occur and seem to act through different pathways in producing dementia. OBJECTIVE: To examine cerebrovascular disease and AD markers in relation to brain glucose metabolism in patients with mild cognitive impairment. DESIGN AND SETTING: Cohort study among the Alzheimer Disease Neuroimaging Initiative clinical sites in the United States and Canada. PARTICIPANTS: Two hundred three patients having amnestic mild cognitive impairment (74 of whom converted to AD) with serial imaging during a 3-year follow-up period. MAIN OUTCOMES AND MEASURES: Quantified white matter hyperintensities (WMHs) represented cerebrovascular disease, and cerebrospinal fluid β-amyloid represented AD pathology. Brain glucose metabolism in temporoparietal and frontal brain regions was measured using positron emission tomography with fluorodeoxyglucose F18. RESULTS: In converters, greater WMHs were associated with decreased frontal metabolism (-0.048; 95% CI, -0.067 to -0.029) but not temporoparietal metabolism (0.010; 95% CI, -0.010 to 0.030). Greater cerebrospinal fluid β-amyloid (per 10-pg/mL increase) was associated with increased temporoparietal metabolism (0.005; 95% CI, 0.000-0.010) but not frontal metabolism (0.002; 95% CI, -0.004 to 0.007) in the same patients. In nonconverters, similar relationships were observed except for a positive association of greater WMHs with increased temporoparietal metabolism (0.051; 95% CI, 0.027-0.076). CONCLUSIONS AND RELEVANCE: The dissociation of WMHs and cerebrospinal fluid β-amyloid in relation to regional glucose metabolism suggests that these pathologic conditions operate through different and independent pathways in AD that reflect dysfunction in different brain systems. The positive association of greater WMHs with temporoparietal metabolism suggests that these pathologic processes do not co-occur in nonconverters.
IMPORTANCE: Cerebrovascular disease and Alzheimer disease (AD) frequently co-occur and seem to act through different pathways in producing dementia. OBJECTIVE: To examine cerebrovascular disease and AD markers in relation to brain glucose metabolism in patients with mild cognitive impairment. DESIGN AND SETTING: Cohort study among the Alzheimer Disease Neuroimaging Initiative clinical sites in the United States and Canada. PARTICIPANTS: Two hundred three patients having amnestic mild cognitive impairment (74 of whom converted to AD) with serial imaging during a 3-year follow-up period. MAIN OUTCOMES AND MEASURES: Quantified white matter hyperintensities (WMHs) represented cerebrovascular disease, and cerebrospinal fluid β-amyloid represented AD pathology. Brain glucose metabolism in temporoparietal and frontal brain regions was measured using positron emission tomography with fluorodeoxyglucoseF18. RESULTS: In converters, greater WMHs were associated with decreased frontal metabolism (-0.048; 95% CI, -0.067 to -0.029) but not temporoparietal metabolism (0.010; 95% CI, -0.010 to 0.030). Greater cerebrospinal fluid β-amyloid (per 10-pg/mL increase) was associated with increased temporoparietal metabolism (0.005; 95% CI, 0.000-0.010) but not frontal metabolism (0.002; 95% CI, -0.004 to 0.007) in the same patients. In nonconverters, similar relationships were observed except for a positive association of greater WMHs with increased temporoparietal metabolism (0.051; 95% CI, 0.027-0.076). CONCLUSIONS AND RELEVANCE: The dissociation of WMHs and cerebrospinal fluid β-amyloid in relation to regional glucose metabolism suggests that these pathologic conditions operate through different and independent pathways in AD that reflect dysfunction in different brain systems. The positive association of greater WMHs with temporoparietal metabolism suggests that these pathologic processes do not co-occur in nonconverters.
Authors: Laurel A Beckett; Danielle J Harvey; Anthony Gamst; Michael Donohue; John Kornak; Hao Zhang; Julie H Kuo Journal: Alzheimers Dement Date: 2010-05 Impact factor: 21.566
Authors: Clifford R Jack; Matt A Bernstein; Bret J Borowski; Jeffrey L Gunter; Nick C Fox; Paul M Thompson; Norbert Schuff; Gunnar Krueger; Ronald J Killiany; Charles S Decarli; Anders M Dale; Owen W Carmichael; Duygu Tosun; Michael W Weiner Journal: Alzheimers Dement Date: 2010-05 Impact factor: 21.566
Authors: John Q Trojanowski; Hugo Vandeerstichele; Magdalena Korecka; Christopher M Clark; Paul S Aisen; Ronald C Petersen; Kaj Blennow; Holly Soares; Adam Simon; Piotr Lewczuk; Robert Dean; Eric Siemers; William Z Potter; Michael W Weiner; Clifford R Jack; William Jagust; Arthur W Toga; Virginia M-Y Lee; Leslie M Shaw Journal: Alzheimers Dement Date: 2010-05 Impact factor: 21.566
Authors: S M Landau; D Harvey; C M Madison; E M Reiman; N L Foster; P S Aisen; R C Petersen; L M Shaw; J Q Trojanowski; C R Jack; M W Weiner; W J Jagust Journal: Neurology Date: 2010-06-30 Impact factor: 9.910
Authors: Gad A Marshall; Dorene M Rentz; Meghan T Frey; Joseph J Locascio; Keith A Johnson; Reisa A Sperling Journal: Alzheimers Dement Date: 2011-05 Impact factor: 21.566
Authors: Owen Carmichael; Christopher Schwarz; David Drucker; Evan Fletcher; Danielle Harvey; Laurel Beckett; Clifford R Jack; Michael Weiner; Charles DeCarli Journal: Arch Neurol Date: 2010-11
Authors: Clifford R Jack; David S Knopman; William J Jagust; Leslie M Shaw; Paul S Aisen; Michael W Weiner; Ronald C Petersen; John Q Trojanowski Journal: Lancet Neurol Date: 2010-01 Impact factor: 44.182
Authors: R C Petersen; P S Aisen; L A Beckett; M C Donohue; A C Gamst; D J Harvey; C R Jack; W J Jagust; L M Shaw; A W Toga; J Q Trojanowski; M W Weiner Journal: Neurology Date: 2009-12-30 Impact factor: 9.910
Authors: Timothy M Hughes; Lewis H Kuller; Emma J M Barinas-Mitchell; Eric M McDade; William E Klunk; Ann D Cohen; Chester A Mathis; Steven T Dekosky; Julie C Price; Oscar L Lopez Journal: JAMA Neurol Date: 2014-05 Impact factor: 18.302
Authors: Ge Li; Steven P Millard; Elaine R Peskind; Jing Zhang; Chang-En Yu; James B Leverenz; Cynthia Mayer; Jane S Shofer; Murray A Raskind; Joseph F Quinn; Douglas R Galasko; Thomas J Montine Journal: JAMA Neurol Date: 2014-06 Impact factor: 18.302
Authors: Timothy C Durazzo; Magdalena Korecka; John Q Trojanowski; Michael W Weiner; Ruth O' Hara; John W Ashford; Leslie M Shaw Journal: J Alzheimers Dis Date: 2016-07-25 Impact factor: 4.472
Authors: Vijay K Ramanan; Scott A Przybelski; Jonathan Graff-Radford; Anna M Castillo; Val J Lowe; Michelle M Mielke; Rosebud O Roberts; Robert I Reid; David S Knopman; Clifford R Jack; Ronald C Petersen; Prashanthi Vemuri Journal: J Alzheimers Dis Date: 2018 Impact factor: 4.472
Authors: Timothy C Durazzo; Niklas Mattsson; Michael W Weiner; Magdalena Korecka; John Q Trojanowski; Leslie M Shaw Journal: Drug Alcohol Depend Date: 2014-07-03 Impact factor: 4.492